We use what's inherent in our biology to remove the guesswork
Epigenetics impacts how strongly your genetic traits are expressed.
Your genes are determined by your DNA, made up of adenine (A), cytosine (C), guanine (G) and thymine (T) molecules that spell out a code that tells your body how to express various genetic traits.
When methyl groups are present on cytosine molecules within DNA, the genetic code doesn't change, but it is blocked from functioning, essentially turning the trait off.
We refer to this genetic modification process as epigenetics—and it's the basis of our platform at Inherent Biosciences.
PLATFORM
By studying the epigenetic patterns found in cells, we have identified specific profiles that indicate how well certain genes are likely to function—genes that are directly related to reproductive health.
We leverage the power of AI and machine learning to look at large data sets of cells' DNA and analyze how epigenetic modifications are correlated to certain disease states and health outcomes.
With these data sets, we're developing diagnostic tools—and eventually therapeutics—that unlock personalized insights and offer actionable guidance to healthcare providers and their patients.
PRODUCT
Path SpermQT is an epigenetic sperm quality test that is designed to predict poor fertility outcomes that are not identified with standard semen analysis alone.
Using our AI epigenetics platform, Path SpermQT assesses gene function related to spermatogenesis and embryo development. It categorizes sperm as excellent, normal, or poor sperm quality based on epigenetic patterns.
These categories are correlated to fertility outcomes when using IUI or IVF, and can help healthcare providers determine which treatment options are more likely to work.
“A lot of infertility goes undiagnosed because men go undiagnosed. And when men go undiagnosed, women go through procedures that will not work.”